Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

696
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
696
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

568
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
568
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

609
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
609
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

523
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
523
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

751
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
751
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

674
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
674

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same author

Supplemental Oxygen Therapy in Advanced Lung Disease-New Evidence Raises New Questions.

Respirology (Carlton, Vic.)·2026
Same author

Palliative care interventions for thoracic cancer: a systematic review and meta-analysis identifying the core elements.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Supporting referral to pulmonary rehabilitation from primary care: A systematic evaluation of interventions using the ERIC taxonomy.

NPJ primary care respiratory medicine·2026
Same author

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

American journal of respiratory and critical care medicine·2026
Same author

Validation and minimum important difference of the chronic respiratory disease questionnaire in patients with interstitial lung disease.

Respiratory medicine·2026

Related Experiment Video

Updated: Mar 8, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.6K

Exercise-based rehabilitation programmes for pulmonary hypertension.

Norman R Morris1,2, Fiona D Kermeen3, Anne E Holland4,5

  • 1Allied Health Research Collaborative, The Prince Charles Hospital, Chermside, Queensland, Australia.

The Cochrane Database of Systematic Reviews
|January 19, 2017
PubMed
Summary
This summary is machine-generated.

Exercise-based rehabilitation significantly improves exercise capacity in individuals with pulmonary hypertension (PH). This approach is safe and shows potential benefits, though more research is needed to confirm its impact on quality of life.

More Related Videos

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

14.1K
A Rehabilitation Program of Exoskeleton-assisted Body Weight-Supported Treadmill Training with Non-immersive Virtual Reality for Stroke Patients
06:00

A Rehabilitation Program of Exoskeleton-assisted Body Weight-Supported Treadmill Training with Non-immersive Virtual Reality for Stroke Patients

Published on: May 16, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 8, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.6K
Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

14.1K
A Rehabilitation Program of Exoskeleton-assisted Body Weight-Supported Treadmill Training with Non-immersive Virtual Reality for Stroke Patients
06:00

A Rehabilitation Program of Exoskeleton-assisted Body Weight-Supported Treadmill Training with Non-immersive Virtual Reality for Stroke Patients

Published on: May 16, 2025

1.3K

Area of Science:

  • Cardiology
  • Pulmonology
  • Rehabilitation Medicine

Background:

  • Pulmonary hypertension (PH) significantly impairs exercise capacity and quality of life.
  • Exercise-based rehabilitation is increasingly explored as a therapeutic intervention for PH patients.
  • Initial concerns about exercise safety in PH have been largely allayed by emerging evidence.

Purpose of the Study:

  • To evaluate the efficacy and safety of exercise-based rehabilitation programs for individuals diagnosed with pulmonary hypertension.
  • To assess the impact of rehabilitation on primary outcomes including exercise capacity, adverse events, and health-related quality of life (HRQoL).
  • To explore secondary outcomes such as cardiopulmonary hemodynamics, functional class, clinical worsening, mortality, and B-type natriuretic peptide levels.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) focusing on exercise-based rehabilitation for PH.
  • Data extraction and analysis by two independent reviewers, employing random-effects models for continuous and binary outcomes.
  • Assessment of risk of bias and quality of evidence using GRADE methodology.

Main Results:

  • Included five RCTs involving participants with pulmonary artery hypertension (PAH).
  • Exercise rehabilitation led to significant improvements in six-minute walk distance (mean difference 60.12m), peak oxygen uptake (2.4 ml/kg/min), and peak power (16.4W).
  • Health-related quality of life showed moderate improvements in physical and mental component scores, though clinical significance varied. One instance of lightheadedness was reported as an adverse event.

Conclusions:

  • Exercise-based rehabilitation demonstrates clinically relevant improvements in exercise capacity for individuals with PH.
  • The intervention appears safe, with no serious adverse events reported across the included studies.
  • While HRQoL improvements were noted, their clinical importance requires further investigation. Low-quality evidence necessitates caution in generalizing findings.